Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
about
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorQuantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.Sunitinib Possible Sex-Divergent Therapeutic Outcomes.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma.[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients.
P2860
Q33432047-53F4E287-44AE-4B4F-9011-5E3BA8F5FE7BQ35450340-4622B8BB-C5B2-4E5E-ABA4-658AC7D27589Q35884179-3654F88A-6016-4F06-8971-86A52839727AQ37038195-9D4B597D-37A0-4AA4-931F-5B1437FC3697Q38627885-B85B4E99-FC35-4702-AD5D-A0D9039C3C21Q38635940-C600E1C5-F5D8-478B-BC0B-AFCA6721C0B2Q38655156-D5658564-8AD7-4599-9E84-423BC980305BQ38664221-54F1723F-E865-4B78-BDD3-D31E55262340Q38869600-ED5F827A-D793-4821-85E1-1B2A62F054E7Q38937228-CDBCBBB2-ED51-415B-91AC-D5F692628DAFQ39065451-7CAF0D84-A5C3-4E9D-BCCE-8486A838B441Q39429946-B07EE242-939F-4B90-A729-DDA04893A811Q39688034-BD3763FC-301D-49D0-8B31-9C2C2C43CD66Q40126912-1543FC51-70FB-41FE-A754-94EA7BB7F76BQ40177329-F6E57A66-034E-47D2-985C-3D1F7A092555Q47637910-94ED8B40-4AAA-4CDD-AD55-6D4AFCF23BA5Q47831824-4332376D-B4B8-4780-B31B-37025540612EQ47847397-9B64491E-7697-4141-A123-A1F1ED07028EQ47895186-D65B4679-491F-4B31-A85C-EBA3FACBC419Q47969048-8CF9B328-A4E1-48CB-8270-A48DED6ADDD9Q48029427-1489B0E4-4F25-453D-85F7-4413C870DC34Q48826707-4033D7D5-9D3F-4489-AC02-F03A6B809E34Q49184931-60775C30-1584-445A-8ADB-F93611F46290Q49722763-A40302BC-EEAF-41AF-BF2D-5BC6E92C67E0Q50600192-5D24A050-11CA-477E-A6FE-1D81C7945B61Q53669584-55B38AF7-EF05-436E-83DB-F3859E84DEAAQ54119194-F86FD554-DB15-407B-BED7-B15FC58FBAC9Q55069281-F883D593-8ABA-498B-8529-E2C29B17E4EBQ55382774-C43E91BF-1F25-49D6-B25D-F4B008C96610
P2860
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacokinetically guided sun ...... s with advanced solid tumours.
@ast
Pharmacokinetically guided sun ...... s with advanced solid tumours.
@en
type
label
Pharmacokinetically guided sun ...... s with advanced solid tumours.
@ast
Pharmacokinetically guided sun ...... s with advanced solid tumours.
@en
prefLabel
Pharmacokinetically guided sun ...... s with advanced solid tumours.
@ast
Pharmacokinetically guided sun ...... s with advanced solid tumours.
@en
P2093
P2860
P356
P1476
Pharmacokinetically guided sun ...... s with advanced solid tumours.
@en
P2093
A D R Huitema
C G M Gadellaa-van Hooijdonk
G A Cirkel
J B A G Haanen
J H Beijnen
J H M Schellens
J S L Kloth
M J A de Jonge
M P J K Lolkema
P2860
P2888
P304
P356
10.1038/BJC.2014.194
P407
P577
2014-04-15T00:00:00Z
P5875
P6179
1021340342